Pfizer announced this past week that they are developing a Global Biotechnology Center in Hangzhou, China. This $350M investment will be Pfizer’s newest addition to their portfolio of biotechnology centers and reinforces China as a leading area for growth in the healthcare space. Integral to it all is GE Healthcare’s KUBio modular facility. GE’s prefabricated modules reportedly cut the build time in half and help the facility reduce CO2, H2O and energy consumption by 75%. Will these savings be reflected in the pricing of Pfizer’s future novel biologics and biosimilars? That could help to lessen some of the recent shade thrown on pharma for its pricing strategies. Not that it’s Pfizer’s responsibility to rescue the industry’s reputation but come on, it’s Pfizer.